Home Healthcare Biotechnology Enteric Disease Testing Market

Enteric Disease Testing Market Size, Share & Trends Analysis Report By Product Type (Reagents and Consumables, Equipment), By Technique (Molecular Diagnostics, Immunodiagnostics), By Disease Type (Bacterial Enteric Disease, Viral Enteric Disease, Parasitic Enteric Disease), By End-User (Academic and Research Institutes, Hospital Laboratories, Pharmaceutical and Biotechnology Companies) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: August 24, 2026 | Author: Debashree Bora | Format:

Enteric Disease Testing Market Size

The global enteric disease testing market size was valued at USD 4.17 billion in 2025 and is projected to grow from USD 4.43 billion in 2026 to USD 7.24 billion by 2034, registering a CAGR of 6.33% during the forecast period from 2026 to 2034. North America dominated the enteric disease testing market with a market share of 37.4% in 2025.

Enteric disease testing diagnoses infections and diseases that affect the gastrointestinal tract, specifically the stomach and intestines. These diseases are typically caused by various pathogens, including bacteria, viruses, and parasites, and can result in symptoms such as diarrhea, vomiting, stomach pain, and fever. Enteric disease testing is critical for identifying the causative agents of gastrointestinal infections, making informed treatment decisions, and implementing public health measures to prevent the spread of infectious diseases.

Furthermore, the rising incidence rates of shigellosis, Clostridium difficile (C. difficile), campylobacteriosis, cholera, Escherichia coli (E. coli), salmonellosis, and cholera, all of which can cause severe diarrhea or death, are driving the growth of the enteric disease testing market share.

Moreover, the untapped enteric disease testing market in developing countries provides a significant opportunity for healthcare companies to create innovative and cost-effective testing solutions to meet the population's unmet needs. Furthermore, the rise in the trend of enteric disease testing, the increase in awareness of enteric disease testing diagnosis in developing countries such as China and India, the increase in disposable income, the increase in funding, and the rise in the discovery and development of effective enteric disease testing products all contribute to the growth of the enteric disease testing industry.

Enteric Disease Testing Market Size

Download a Free Sample To learn more about this report.

Product Type Analysis

The market is further segmented by product type into Reagents, Consumables, and Equipment.

The reagents and consumables segment accounted for most of the enteric disease testing market share in 2023, owing to the high adoption of reagents and consumables, increased availability of reagents and consumables, and companies experiencing high reagent and consumable sales. Enteric disease testing procedures require reagents and consumables to prepare samples, perform assays, and generate test results. These include the chemicals, buffers, enzymes, antibodies, and other biochemical substances needed for sample processing, nucleic acid extraction, amplification, and detection of enteric pathogens. Reagents and consumables are typically tailored to specific testing methods, such as molecular diagnostics, immunoassays, and culture-based techniques.

The equipment segment is expected to grow fastest during the forecast period, owing to the short testing time, the ability to run multiple samples simultaneously, increased accuracy, and the high demand for automation for enteric disease testing. Enteric disease testing laboratories use equipment to perform diagnostic assays, analyze samples, and generate test results. This includes laboratory instruments like PCR machines, real-time PCR systems, microplate readers, automated liquid handling systems, incubators, centrifuges, and specialized diagnostic platforms for detecting enteric pathogens.

Enteric Disease Testing Market Size By Segments

Request Customizationto receive a tailored report.

technique Analysis

The market is fragmented into Molecular Diagnostics and immunodiagnostics.

The immunodiagnostics segment generated the most revenue in 2023, owing to increased adoption of immunodiagnostic techniques and advancements in immunodiagnostic technology. Immunodiagnostics is a technique in enteric disease testing that detects and measures immune responses to enteric pathogens. This method employs antibodies, antigens, and immunological assays such as enzyme-linked immunosorbent assays (ELISAs), lateral flow assays, and immunofluorescence assays to detect specific antigens or antibodies associated with enteric infections.

The molecular diagnostics segment is expected to grow at the fastest CAGR during the forecast period, owing to increased demand for molecular diagnostics products, increased use of molecular diagnostics techniques in research, and increased availability of molecular diagnostics equipment. Immunodiagnostics is a technique in enteric disease testing that detects and measures immune responses to enteric pathogens.

Disease Type Analysis

The market can be further bifurcated by disease type into Bacterial Enteric Diseases, Viral Enteric Diseases, and Parasitic Enteric Diseases.

The bacterial enteric disease segment had the highest market share in 2023, owing to the large number of people suffering from Clostridium difficile (C. difficile), campylobacteriosis, cholera, Escherichia coli (E. coli), Helicobacter pylori (H. pylori), salmonellosis, and the widespread use of enteric disease testing products for the diagnosis of bacterial enteric diseases. The same segment is expected to grow at the fastest CAGR during the forecast period, owing to increased awareness about bacterial enteric disease diagnosis and prevalence worldwide.

Additionally, these pathogens can spread through contaminated food and water, person-to-person, or animal contact. Bacterial enteric diseases pose significant public health challenges worldwide, frequently linked to foodborne illness, waterborne outbreaks, and inadequate sanitation.

Viral enteric diseases are caused by viruses that infect the gastrointestinal tract, resulting in symptoms like diarrhea, vomiting, abdominal cramps, and fever. Norovirus, rotavirus, adenovirus, astrovirus, and enteric viruses like hepatitis A and E are among the most common viral enteric pathogens. Viral enteric diseases are highly contagious and spread quickly via fecal-oral transmission, contaminated food and water, and person-to-person contact.

end-User Analysis

The market is fragmented into Academic and Research Institutes, Hospital Laboratories, and Pharmaceutical and Biotechnology Companies.

The hospital laboratories segment generated the most revenue in 2023, thanks to increased health coverage for hospital-based treatment, hospital admissions, and a greater preference for hospital laboratories. The same segment is expected to grow at the fastest CAGR during the forecast period, owing to an increase in the diagnosis of enteric diseases in hospital laboratories and an increase in awareness of routine body checkups.

Moreover, bacterial culture, molecular assays, antigen detection tests, and serological testing are among the diagnostic tests for enteric pathogens performed by hospital laboratories. These laboratories play an important role in patient care by providing timely and accurate test results, guiding treatment decisions, and facilitating infection prevention measures.

Pharmaceutical and biotechnology companies are responsible for developing, manufacturing, and commercializing enteric disease testing products such as reagents, consumables, equipment, and diagnostic assays. These companies invest in R&D to create new diagnostic technologies, improve assay performance, and broaden the number of enteric pathogens detected.

Enteric Disease Testing Market Share By Segments

Speak to an Analystto discuss market opportunities.

Regional Insights

The global enteric disease testing market share is bifurcated into North America, Europe, Asia-Pacific, the Middle East and Africa, and Latin America.

North America Dominates the Global Market

North America is the most significant global enteric disease testing market shareholder and is estimated to grow at a CAGR of 3.3% over the forecast period. The presence of several important players in the region, including Abbott Laboratories, Becton Dickinson & Company, Biomerica, Inc., Bio-Rad Laboratories, Inc., Meridian Bioscience, Inc., and Quest Diagnostics, as well as advancements in manufacturing technology for enteric disease testing products, drive market growth. This is primarily due to the increased number of patients suffering from enteric diseases, increased government funding for research into enteric disease diagnosis, and a significant increase in capital income in developed countries.

Furthermore, a sophisticated reimbursement structure aimed at lowering expenditure levels fuels enteric disease testing market growth. Thus, such factors drive market growth. Moreover, the United States is expected to contribute a significant share of the regional market and drive the development of the enteric disease testing market over the forecast period. The well-established healthcare infrastructure, high purchasing power, and increased adoption of enteric disease testing are expected to drive market growth.

North America Enteric Disease Testing Market Revenue Share 2025

Unlock Regional Insightsto access country-level data, & regional trends.

Europe: Fastest-Growing Region

Europe is anticipated to exhibit a CAGR of 3.0% over the forecast period, accounting for the second-largest revenue share at 30%.Germany dominates the European market, owing to its large senior population. According to United Nations population data, one in every 20 people in Germany is over 80, expected to rise to one in every six by 2050. People over the age of 65 represented 22.4% of the total population. In 2019, 90.4 million people over 65 lived in Europe. Problems with the growing senior population include an increased risk of enteric diseases caused by senescence and decreased immunity levels. Rapid diagnostic techniques like point-of-care diagnostic devices can benefit this population. Key manufacturers, including Roche and Bio-Rad, are expanding their operations in Germany, which is expected to boost the enteric disease testing industry.

Asia-Pacific is expected to grow at the fastest CAGR over the forecast period as people become more aware of the importance of testing and the increase in infections. Attractive market regions are located in developing nations such as China and India, resulting in Asia Pacific's fastest growth. Enteric diseases are more prevalent in Asian countries. For example, Bangladesh has the highest typhoid case rate, with 252 cases per 100,000 people.

Latin America is expected to experience moderate growth over the forecast period. Brazil is expected to provide significant opportunities for market growth. Brazil has experienced positive economic growth due to increased financial and political stability. Healthcare reforms, such as the Unified Health System (SUS), offer free healthcare services to people of all income levels without charging additional fees. The SUS consists of public, private, and supplemental healthcare services.

Additionally, government initiatives, such as collaboration between the United States and Brazil on biomedical research to accelerate R&D in diagnosing and treating infectious diseases, are also boosting the market. However, access to advanced diagnostics in Brazil is currently restricted to urban areas due to a need for more infrastructure in rural areas, which may slow market growth.

List of Key and Emerging Players in Enteric Disease Testing Market

Abbott Laboratories
Bio-Rad Laboratories Inc
Diasorin SpA
Trinity Biotech
Meridian Bioscience Inc
Coris BioConcept
Quest Diagnostics Inc
Biomerica, Inc
Biomerieux SA
Becton Dickinson & Company

Key Industry Developments

October 2025
BD received U.S. FDA 510(k) clearance for the BD Enteric Bacterial Panel and BD Enteric Bacterial Panel Plus for the BD COR System. The approval expands BD's molecular diagnostics portfolio with automated syndromic testing for major bacterial gastrointestinal pathogens.
August 2025
QIAGEN received U.S. FDA clearance for the QIAstat-Dx Gastrointestinal Panel 2 Mini B. The panel strengthens the company's syndromic testing portfolio by enabling rapid detection of five major bacterial causes of gastrointestinal infections in outpatient settings.
July 2025
bioMérieux expanded its BIOFIRE gastrointestinal diagnostics portfolio through new software and workflow enhancements for the BIOFIRE FilmArray system, improving laboratory efficiency and supporting faster diagnosis of enteric infections.
June 2025
Seegene expanded the commercialization of its multiplex gastrointestinal molecular diagnostic assays across Europe and Asia-Pacific, strengthening its syndromic testing portfolio for bacterial, viral, and parasitic enteric pathogens.

Report Scope

Segmentation

By Product Type 2
  • Reagents and Consumables
  • Equipment
By Technique 2
  • Molecular Diagnostics
  • Immunodiagnostics
By Disease Type 3
  • Bacterial Enteric Disease
  • Viral Enteric Disease
  • Parasitic Enteric Disease
By End-User 3
  • Academic and Research Institutes
  • Hospital Laboratories
  • Pharmaceutical and Biotechnology Companies

Geographies Covered

North America 2
  • U.S.
  • Canada
Europe 8
  • U.K.
  • Germany
  • France
  • Spain
  • Italy
  • Russia
  • Nordic
  • Benelux
APAC 8
  • China
  • Korea
  • Japan
  • India
  • Australia
  • Singapore
  • Taiwan
  • South East Asia
Middle East and Africa 6
  • UAE
  • Turkey
  • Saudi Arabia
  • South Africa
  • Egypt
  • Nigeria
LATAM 5
  • Brazil
  • Mexico
  • Argentina
  • Chile
  • Colombia
Competitive Coverage Abbott Laboratories · Bio-Rad Laboratories Inc · Diasorin SpA · Trinity Biotech · Meridian Bioscience Inc
Research Deliverables Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends

Customize This Report to Match Your Strategic Objectives

Frequently Asked Questions (FAQs)

The enteric disease testing market size is valued at USD 4.43 Billion in 2026 and is projected to reach USD 7.24 Billion by 2034, at a CAGR of 6.33% during the forecast period 2026-2034.

North America dominated the market with a share of 37.4% in 2025.

The leading players in this market are Abbott Laboratories, Bio-Rad Laboratories Inc, Diasorin SpA, Trinity Biotech, Meridian Bioscience Inc.

The enteric disease testing market is projected to grow at a CAGR of 6.33% during the forecast period of 2026 2034.
About the Author
Debashree Bora
Debashree Bora
Healthcare Lead

Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, and competitive dynamics.
Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.

Report Details
−
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Request Sample Order Report Now

We are featured on: